www.marijuanamoment.net
Open in
urlscan Pro
172.67.214.33
Public Scan
URL:
https://www.marijuanamoment.net/cbd-is-effective-in-treating-anxiety-depression-and-poor-sleep-study-finds/
Submission: On May 30 via manual from US — Scanned from US
Submission: On May 30 via manual from US — Scanned from US
Form analysis 3 forms found in the DOM
GET https://www.marijuanamoment.net/
<form method="get" id="searchform" action="https://www.marijuanamoment.net/">
<input type="text" name="s" id="s" value="Search" onfocus="if (this.value == "Search") { this.value = ""; }" onblur="if (this.value == "") { this.value = "Search"; }">
<input type="hidden" id="searchsubmit" value="Search">
</form>POST
<form id="mc4wp-form-2" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1716984978"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-2">
<div class="mc4wp-response"></div>
</form>POST
<form id="mc4wp-form-3" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1716984978"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-3">
<div class="mc4wp-response"></div>
</form>Text Content
* Politics
* Science & Health
* Culture
* Business
* Video
* Newsletter
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
Connect with us
*
*
*
MARIJUANA MOMENT
CBD IS EFFECTIVE IN TREATING ANXIETY, DEPRESSION AND POOR SLEEP, STUDY FINDS
* Politics
* South African President Signs Marijuana Legalization Bill Into Law
* Delaware Governor Signs Bill To Expand Medical Marijuana Access By Letting
Doctors Recommend It For Any Condition
* Atlanta Could Add Psilocybin And Ketamine To City Workers’ Healthcare
Plans Under Pending Resolution
* New Hampshire Lawmakers Must Legalize Marijuana This Session, Even With A
Less-Than-Ideal Bill (Op-Ed)
* Missouri Marijuana Revenue Is Funding Veterans Programs, Drug Treatment
And Public Defender Services
* Science & Health
* CBD Is Effective In Treating Anxiety, Depression And Poor Sleep, Study
Finds
* Federal Health Agency Acknowledges Psilocybin’s Therapeutic Potential And
Touts Forthcoming Psychedelic Research
* Cannabis Use Before Bedtime Does Not Cause Next-Day Impairment Of
Cognitive Ability Or Driving Performance, Study Shows
* Marijuana Use Linked To Increase In Light Physical Activity, Study
Challenging ‘Lazy Stoner’ Stereotype Finds
* Psychedelic Mushrooms Won’t Make You Believe In God, But They Might Make
You Think Robots Are Conscious, Study Finds
* Culture
* Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark
The Marijuana Holiday
* Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of
4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
* Colorado Amendment Addresses Concerns On Banning Social Media Marijuana
Posts, But Questions On Psychedelics And Other Drugs Remain
* Former Minnesota Governor Jesse Ventura Launches His Own Cannabis Brand,
Fulfilling A ‘Lifelong Dream’
* Marijuana Rolling Paper Company Seeks Content Creator To ‘Get Paid To
Smoke Weed’ For $70,420 Salary
* Business
* States Have Generated Over $20 Billion In Marijuana Tax Revenue Since
First Markets Opened, New Report Finds
* Arkansas Medical Marijuana Dispensary Gets License Revoked Over Alleged
Violations
* New Jersey Set A New Marijuana Sales Record Last Quarter, With Regulators
Touting ‘Historical Highs’ On 4/20 Weekend
* Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State
Across $6 Billion Mark For Recreational Purchases
* Legal Marijuana Purchases In Michigan Spiked In March, Reaching A New
Record High
* Video
* Trump Pledges To Free Silk Road Drug Market Operator Russ Ulbricht,
Despite Calling For Execution Of Drug Sellers
* Top Federal Drug Official Says There’s ‘Tremendous Excitement’ Around
Psychedelic Medicine, But ‘It’s Not Magic’
* New Hampshire Senate Passes Amended Marijuana Legalization Bill, But Key
House Lawmakers Don’t Like Recent Changes
* House Committee Approves Farm Bill Amendment To Ban Most Hemp-Derived
Cannabinoid Products Like Delta-8 THC
* Ted Cruz Suggests Marijuana Rescheduling Might Lead To More People Dying
In Car Crashes From Impaired Driving
* Newsletter
* White House official misstates cannabis rescheduling impact (Newsletter:
May 29, 2024)
* DEA says THCA is not legal hemp (Newsletter: May 28, 2024)
* NH legal cannabis bill heads to final vote (Newsletter: May 27, 2024)
* Military couldn’t test recruits for cannabis under approved bill
(Newsletter: May 24, 2024)
* Fed cannabis lawsuit arguments (Newsletter: May 23, 2024)
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
SCIENCE & HEALTH
CBD IS EFFECTIVE IN TREATING ANXIETY, DEPRESSION AND POOR SLEEP, STUDY FINDS
Published
3 seconds ago
on
May 29, 2024
By
Ben Adlin
New industry-backed research into the potential anti-anxiety effects of
cannabidiol found that an oral CBD solution effectively treated mild to moderate
anxiety, as well as associated depression and poor sleep quality, with no
serious adverse events observed.
“Our findings indicate that administering 300-600 mg of nanodispersible CBD oral
solution for 12 weeks is effective in treating mild to moderate anxiety
disorders and associated depression and sleep quality disturbances,” authors
wrote. “These findings align with the growing body of evidence indicating that
CBD may have anxiolytic effects if administered for a longer duration, ranging
from 4 to 12 weeks.”
The report, published this month in the Asian Journal of Psychiatry, was penned
by a seven-person research team from Asha Hospital and Leiutis Pharmaceuticals
LLP, both in India, and New Jersey-based Biophore Pharma Inc. All authors, the
paper says, participated “as employees of or consultants to Leiutis
Pharmaceuticals,” which funded the study.
CBD Can Help Treat Pain, Cancer, Schizophrenia, COVID And Other Conditions
CBD Can Help Treat Pain, Cancer, Schizophrenia, COVID And Other Conditions
A new scientific review highlights CBD's potential to treat various conditions
such as epilepsy, pain, cancer, schizophrenia, diabetes, and COVID-19. The
review aims to summarize cannabis's impact on human health, noting its
“neuroprotective, anti-inflammatory, and pain-relieving properties”. The study
delves into CBD's pharmacological properties, mechanisms of action, and its
potential medical applications. It discusses CBD's role in treating epilepsy,
pain relief, managing schizophrenia symptoms, and its potential as a COVID-19
inhibitor. The review also touches upon CBD's promising anticancer properties
and its effects on diabetes-related processes. “Cannabis exhibits
neuroprotective, anti-inflammatory, anti-thrombotic, anti-bacterial, analgesic,
and antiepileptic properties.” Additionally, it acknowledges the industrial
applications of CBD and hemp in pharmaceuticals, skincare, fuel, paper,
clothing, rope, and massage oil production.
More Videos
0 seconds of 1 minute, 9 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard ShortcutsEnabledDisabled
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Next Up
Marijuana Users May Have More Empathy
01:05
facebook twitter Email pinterest
Linkhttps://cdn.jwplayer.com/previews/KBYYUj9B
Copied
Live
00:00
01:10
01:09
Use of the CBD solution “showed therapeutic efficacy, excellent safety, and
tolerability in treating not only mild to moderate anxiety disorders (primary
end point of the study), but also associated depression and disturbances in
sleep quality (Secondary endpoint of the study)” the paper says, “with no
incidences of withdrawal anxiety upon dose tapering at the end of the
treatment.”
> “CBD oral solution was effective treating mild to moderate anxiety.”
“Our research supports the importance of investigating the potential
effectiveness of nanodispersible CBD oral solution in treating other forms of
psychiatry disorders,” authors wrote, “and exploring its possible applications
in clinical practice.”
Participants in the study were split into either a CBD or control group. Those
in the CBD group received 300 milligrams of CBD per day at first, which
increased over time to 600 mg per day and was later reduced to 150 mg per day
toward the end of the study period. Those in the control group received a
placebo.
A test of generalized anxiety disorder, GAD-7, found drops in anxiety markers
among participants who took CBD compared to the placebo group. Mean scores
“gradually decreased in the CBD group from week 2 (visit 4), which continued
till week 13,” the study says, noting that the “mean GAD-7 score for CBD arm at
baseline was 11.8±1.52 and the score at the end of treatment (visit-9) was
4.8±1.60, at visit-10 (dose taper) was 3.7±1.27, and at end of study (visit-11)
was 3.1±1.06.”
Among those who took the placebo, the mean anxiety scores hardly changed. “The
mean GAD-7 score (SD) for placebo arm at baseline (visit-3) was 11.2±1.43 and
the score at end of treatment (visit-9) was 11.8±1.73, at Visit-10 (dose taper)
was 11.8±1.72, and end of study (visit-11) was 11.8±1.75,” according to the
report.
Another test, the Hamilton Anxiety Rating Scale (HAM-A), found similar drops in
anxiety measures in CBD participants compared to the placebo group.
> “CBD was therapeutically safe with no serious adverse events, well tolerated,
> and effective for the treatment of mild to moderate anxiety disorders, as well
> as associated depression and sleep quality disturbances.”
“The mean HAM-A score for CBD arm at baseline (visit-3) was 18.9±2.62 and the
score at end of treatment (visit-9) was 7.34±1.77, at visit-10 (dose taper) was
5.83±1.67, and at end of study (visit-11) was 4.57±1.39,” the study says, while
“the mean HAM-A score (SD) for placebo arm at baseline was 18.2±2.75 and the
score at end of treatment was 18.9±2.75, at Visit-10 (dose taper) was 19.0±2.84,
and end of study (visit-11) was 18.9±2.95.”
Participants in the CBD group also had their dosages reduced near the end of the
study period, and no immediate increase in their anxiety was observed.
“At Visit 10 (Week 12), the drug was tapered to 150 mg/day,” the report
describes, “and at the end of the study, at Visit 11 (Week 13), there was no
increase in anxiety scores.”
Separate research published earlier this year found that a component of
marijuana, the terpene D-limonene, may help ease anxiety and paranoia associated
with the psychoactive cannabinoid THC. That study found that subjects who
vaporized limonene along with a dose of THC experienced less anxiety and
paranoia compared to those who consumed THC alone.
Another substance, similar to the psychedelic LSD, was also recently awarded
breakthrough therapy status by the Food and Drug Administration (FDA) for the
treatment of generalized anxiety disorder. The drugmaker behind the substance,
known as MM120, said at the time that it plans to hold an end-of-Phase 2 meeting
with FDA in the first half of 2024 and begin a Phase 3 clinical trial in the
second half of the year.
According to a media representative the drugmaker, MindMed, MM120 is “a tartrate
salt form of lysergide, a synthetic drug commonly known as LSD.”
The breakthrough designation is the latest in a series of developments around
psychedelic-based therapies. Late last year, FDA granted priority status to its
review of MDMA-assisted therapy as a potential treatment option for
post-traumatic stress disorder (PTSD). The agency has set a target date to make
a determination by August 11, according to applicant Lykos Therapeutics
(formerly named MAPS Public Benefit Corporation).
If the new drug application is ultimately approved, the Drug Enforcement
Administration (DEA) would then need to reschedule MDMA accordingly. It would
become the first psychedelic in history to be approved as a pharmaceutical, to
be administered in tandem with talk therapy and other supportive services.
As for CBD and anxiety, a separate study earlier this year found that dogs
receiving daily doses of CBD saw “significant reductions” in stress and anxiety
related to car travel.
All 20 dogs involved in that study, published in the Journal of Animal Science,
exhibited signs of stress and anxiety when riding in a car, but canines treated
with CBD two hours before taking the trip showed meaningful improvements over a
24-week review period.
> Cannabis Use Before Bedtime Does Not Cause Next-Day Impairment Of Cognitive
> Ability Or Driving Performance, Study Shows
Photo courtesy of Kimzy Nanney.
Marijuana Moment is made possible with support from readers. If you rely on our
cannabis advocacy journalism to stay informed, please consider a monthly Patreon
pledge.
Related Topics:featured
Don't Miss
Federal Health Agency Acknowledges Psilocybin’s Therapeutic Potential And Touts
Forthcoming Psychedelic Research
Ben Adlin
Ben Adlin, a senior editor at Marijuana Moment, has been covering cannabis and
other drug policy issues professionally since 2011. He was previously a senior
news editor at Leafly, an associate editor at the Los Angeles Daily Journal and
a Coro Fellow in Public Affairs. He lives in Washington State.
YOU MAY LIKE
White House official misstates cannabis rescheduling impact (Newsletter: May 29,
2024)
South African President Signs Marijuana Legalization Bill Into Law
Delaware Governor Signs Bill To Expand Medical Marijuana Access By Letting
Doctors Recommend It For Any Condition
Atlanta Could Add Psilocybin And Ketamine To City Workers’ Healthcare Plans
Under Pending Resolution
New Hampshire Lawmakers Must Legalize Marijuana This Session, Even With A
Less-Than-Ideal Bill (Op-Ed)
Missouri Marijuana Revenue Is Funding Veterans Programs, Drug Treatment And
Public Defender Services
Advertisement
MARIJUANA NEWS IN YOUR INBOX
Get our daily newsletter.
Email address:
Leave this field empty if you're human:
SUPPORT MARIJUANA MOMENT
*
*
*
* About Marijuana Moment
* Subscribe
* Sponsorship and Advertising
* Privacy Policy
All the cannabis news you need, all in one place. Copyright © 2017-2024
Marijuana Moment LLC ® and Tom Angell
Information from your device can be used to personalize your ad experience.
Do not sell or share my personal information.
A Raptive Partner Site
✕
Do not sell or share my personal information.
You have chosen to opt-out of the sale or sharing of your information from this
site and any of its affiliates. To opt back in please click the "Customize my ad
experience" link.
This site collects information through the use of cookies and other tracking
tools. Cookies and these tools do not contain any information that personally
identifies a user, but personal information that would be stored about you may
be linked to the information stored in and obtained from them. This information
would be used and shared for Analytics, Ad Serving, Interest Based Advertising,
among other purposes.
For more information please visit this site's Privacy Policy.
CANCEL
CONTINUE
MARIJUANA NEWS IN YOUR INBOX
Get our daily newsletter.
Email address:
Leave this field empty if you're human:
×